Brenipatide
DrugAdministered SC
Other names: LY3537031
NCT Number: NCT07223840
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.
Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period.
Interested in participating?
Request InfoHealthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered SC
Other names: LY3537031
Administered SC
Time frame: Week 1 to Week 24
Time frame: Week 1 to Week 24
Time frame: Baseline, Week 24
Time frame: Baseline, Week 24
Time frame: Baseline up to Week 24
Time frame: Baseline up to Week 24
Interested in participating?
Request InfoEli Lilly and Company
Industry
A Phase 2, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for Reduction in Risk of Relapse to Cigarette Smoking in Adults (RENEW-Smk-1)
Acronym: RENEW-Smk-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06926608
Behavior, Health Behavior
Rochester, New York, United States
View Trial DetailsNCT07826728
Behavior, Mouth Diseases
Bolu, Central, Turkey (Türkiye)
View Trial DetailsNCT06693700
Behavior, Behavior, Addictive
Basking Ridge, New Jersey, United States
View Trial DetailsNCT06582693
Behavior, Health Behavior
Philadelphia, Pennsylvania, United States
View Trial Details